Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.
Kawachi H, Kunimasa K, Kukita Y, Nakamura H, Honma K, Kawamura T, Inoue T, Tamiya M, Kuhara H, Nishino K, Mizote Y, Akazawa T, Tahara H, Kumagai T.
Kawachi H, et al. Among authors: kukita y.
Immunotherapy. 2021 Jul;13(10):799-806. doi: 10.2217/imt-2020-0311. Epub 2021 May 25.
Immunotherapy. 2021.
PMID: 34030451
Free article.